Peptech reports 'outstanding' results

Biotech Peptech announced what it described as "outstanding" results from pre-clinical trials on its anti-Tumour Necrosis Factor (anti-TNF) antibody as a treatment for rheumatoid arthritis (RA).

The domain antibody (dAb) has been co-developed with Domantis, and was claimed in a blind trial to completely prevent the onset of RA. In the trial, conducted by an independent third party, Peptech's improved anti-TNF dAb was claimed to completely prevent the onset of arthritis when used in an equivalent dose to established treatments.

"The results of the trial were overwhelmingly positive," said Stephen Kwik, managing director of Peptech. "To have got where we have so fast is really impressive. It has only been fourteen months (in development) which is incredibly fast," he added.

Kwik attributed the drug's speedy genesis to its TNF antibody classification. He said the fact it was a known compound - such as Remicade - made it easier to come up with a product more quickly than usual.

"This could prove to be our real second generation product. We know already that it will be incredibly useful to Peptech, not just on its own but in future as we expand ways to use any future developments," Kwik said.

The domain antibody approach brings with it many advantages, mainly due to the small molecule size. Kwik noted that this offers both cost savings, and more importantly, opens up new delivery options such as the use of inhalers.

Peptech is keen to promote the use of dAbs as a theraupeutic approach to other common diseases such as psoriasis and Crohn's disease, and although not willing to specify areas and times, Kwik admitted the company was busy working on the next stages in approvals ocross a range of products.

"The total market for these products is something like US$3billion. It will open up lots of opportunities for us, and we are really excited about the prospects. We will be taking things further, and anticipate further trials," he said.